Calliditas Therapeutics AB
STO:CALTX

Watchlist Manager
Calliditas Therapeutics AB Logo
Calliditas Therapeutics AB
STO:CALTX
Watchlist
Price: 208 SEK 0.87%
Market Cap: 12.5B SEK
Have any thoughts about
Calliditas Therapeutics AB?
Write Note

Calliditas Therapeutics AB
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Calliditas Therapeutics AB
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Calliditas Therapeutics AB
STO:CALTX
Cash from Financing Activities
kr196.1m
CAGR 3-Years
N/A
CAGR 5-Years
-22%
CAGR 10-Years
N/A
Orexo AB
STO:ORX
Cash from Financing Activities
-kr16.1m
CAGR 3-Years
N/A
CAGR 5-Years
20%
CAGR 10-Years
N/A
Camurus AB
STO:CAMX
Cash from Financing Activities
kr1.3B
CAGR 3-Years
113%
CAGR 5-Years
28%
CAGR 10-Years
N/A
S
Swedencare AB (publ)
STO:SECARE
Cash from Financing Activities
-kr298.5m
CAGR 3-Years
N/A
CAGR 5-Years
-99%
CAGR 10-Years
N/A
IRLAB Therapeutics AB
STO:IRLAB A
Cash from Financing Activities
kr23.7m
CAGR 3-Years
-55%
CAGR 5-Years
-29%
CAGR 10-Years
N/A
I
InDex Pharmaceuticals Holding AB
STO:FLERIE
Cash from Financing Activities
kr571.6m
CAGR 3-Years
6%
CAGR 5-Years
36%
CAGR 10-Years
N/A
No Stocks Found

Calliditas Therapeutics AB
Glance View

Market Cap
12.5B SEK
Industry
Pharmaceuticals

Calliditas Therapeutics AB, a biopharmaceutical company based in Sweden, has carved a niche for itself in the realm of specialty pharmaceuticals, particularly focusing on rare diseases. The company stands out with its dedication to developing novel treatments for orphan conditions that traditionally go under-addressed by larger pharmaceutical entities. Pivotal to its identity, Calliditas leverages its expertise in renal and hepatic diseases, emphasizing precision medicine aimed at improving the lives of patients with severe unmet medical conditions. Their flagship product, Nefecon, is a testament to their approach—designed to treat primary IgA nephropathy, a debilitating kidney disorder. By developing Nefecon with a patient-centric mindset, Calliditas aims to transform the treatment landscape, showcasing its commitment to innovation and regulatory expertise. Revenue generation at Calliditas primarily revolves around the commercialization of its niche therapeutic solutions. The company operates through a well-structured business model that includes strategic partnerships, licensing agreements, and direct market entry. Profits are garnered through successfully translating their clinical research into approved drugs that address critical needs in the healthcare sector. In tandem with developing their portfolio, Calliditas maximizes opportunities within established and emerging markets, ensuring that their highly specialized medicines reach the patients who need them most. This strategic focus not only secures their financial standing but also emphasizes their pivotal role as a pivotal player in rare disease treatment. The resultant revenue stream and successful collaborations underscore Calliditas's capability to marry scientific advancement with commercial viability, ensuring sustainable growth in a competitive pharmaceutical landscape.

CALTX Intrinsic Value
719.43 SEK
Undervaluation 71%
Intrinsic Value
Price

See Also

What is Calliditas Therapeutics AB's Cash from Financing Activities?
Cash from Financing Activities
196.1m SEK

Based on the financial report for Jun 30, 2024, Calliditas Therapeutics AB's Cash from Financing Activities amounts to 196.1m SEK.

What is Calliditas Therapeutics AB's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-22%

Over the last year, the Cash from Financing Activities growth was -28%.

Back to Top